Announcement PDF RNS Number : 9038I Shield Therapeutics PLC 18 June 2026 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Results of 2026 Annual General Meeting London, UK, 18 June 2026: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anemia ("ID/IDA"), announces the voting results for each resolution set out in the Notice of Annual General Meeting 2026. The Board reports that all resolutions were passed: 1 to 12 passed as ordinary resolutions and 13 and 14 passed as special resolutions. The following table shows the votes cast on each resolution: VOTES FOR % VOTES AGAINST % WITHHELD VOTES Resolution 1 663,423,759 99.99% 83,973 0.01% 612,706 Resolution 2 663,165,096 99.96% 259,840 0.04% 695,502 Resolution 3 662,822,843 99.91% 602,093 0.09% 695,502 Resolution 4 663,131,934 99.96% 267,835 0.04% 720,669 Resolution 5 662,884,358 99.92% 540,585 0.08% 695,495 Resolution 6 663,146,757 99.96% 253,012 0.04% 720,669 Resolution 7 662,771,376 99.91% 628,393 0.09% 720,669 Resolution 8 663,346,163 99.97% 189,245 0.03% 585,030 Resolution 9 661,191,218 99.65% 2,342,764 0.35% 586,456 Resolution 10 660,806,346 99.56% 2,944,366 0.44% 369,726 Resolution 11 660,769,857 99.55% 2,978,561 0.45% 372,020 Resolution 12 658,773,200 99.24% 5,058,591 0.76% 288,647 Resolution 13 658,492,989 99.21% 5,225,392 0.79% 402,057 Resolution 14 658,549,598 99.26% 4,920,741 0.74% 650,099 Notes: 1. Number of shares in issue 1,069,524,125. 2. Details of the votes received on the resolutions are available on the Company's website: https://shieldtherapeutics.com/financials. 3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71. For further information please contact: Shield Therapeutics plc www.shieldtherapeutics.com Anders Lundstrom, CEO Stephanie Hicks, Investor Relations https://shieldtherapeutics.com/link/PGXDzy +44 (0) 191 511 8500 Investorrelations@shieldtx.com Nominated Adviser and Joint Broker Peel Hunt LLP James Steel +44 (0)20 7418 8900 Joint Broker Cavendish Ltd Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward +44 (0)20 7220 0500 About Iron Deficiency and ACCRUFeR®/FeRACCRU® Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak). ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well- tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com. About Shield Therapeutics plc Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. to include pediatric patients 10 years of age and older with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., to include pediatric patients 12 years of age and older and also have marketing rights in Australia and New Zealand. FeRACCRU® is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan. ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s. ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RAGMZGMVKRNGVZM